Study of tilrekimig for moderate-to-severe eczema
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests an investigational medicine called tilrekimig for people with moderate-to-severe eczema that hasn't improved with topical treatments. It aims to see if the medicine can reduce eczema symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You have had moderate-to-severe eczema for at least 1 year.
- Topical treatments (such as creams or ointments) have not worked well for you.
- You do not have a significant autoimmune disease, active infection, weakened immune system, significant psychiatric condition, or major liver, kidney, or blood problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medicine called Tilrekimig for people with moderate-to-severe eczema (atopic dermatitis) that hasn't improved with standard treatments. It aims to see if the medicine can reduce symptoms and improve quality of life.
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This study tests whether combining two drugs, dupilumab and tofacitinib, works better for moderate to severe eczema in adults than either alone. It may help people whose eczema is not well controlled with standard treatments.
This trial tests a new medication for people with moderate-to-severe eczema. It aims to see if the treatment is safe and effective for reducing symptoms.
This study compares a new injectable medicine (IBI3027) to an approved one (Dupilumab) for people with moderate-to-severe eczema. If you join, you'll receive one of the two treatments to see if the new one works as well for reducing itching and skin symptoms.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.